Eli Lilly and Company (TSX:LLY)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.46T +61.4% |
| Revenue (ttm) | 113.13B +49.6% |
| Net Income | 37.93B +93.6% |
| EPS | 42.30 +94.8% |
| Shares Out | n/a |
| PE Ratio | 38.60 |
| Forward PE | 28.19 |
| Dividend | 0.24 (0.58%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 131,473 |
| Open | 42.33 |
| Previous Close | 42.35 |
| Day's Range | 41.26 - 43.27 |
| 52-Week Range | 26.53 - 46.26 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study
Eli Lilly (LLY) announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo – orforglipron – vs. titrated insulin glargine in adults with type…
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-...
Lilly's new weight loss combo drug outperforms tirzepatide in latest trial
Eli Lilly reported positive results from a study following EloraTZP, its experimental combo weight loss drug, noting that patients lost an average of 23.3% of their body weight.
Eli Lilly Stock (LLY) Moves Higher on Positive Trial Results for Zepbound Combo
The company has developed several medications for weight loss and diabetes.
Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Lilly says participants on EloraTZP lost up to average 23.3% of weight in study
Eli Lilly (LLY) announced “positive” results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP. Eloralintide alone reduced body weight by up to an average of 28.6…
Eli Lilly announces results of Phase 2b trial of EloraTZP
Eli Lilly (LLY) and Company announced results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist,...
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk fo...
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Eli Lilly said its experimental combination regimen showed greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type 2 dia...
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% co...
A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study
A drug combination studied in people with Type 2 diabetes lowered blood sugar and helped people lose more weight than with Zepbound alone.
Eli Lilly says ebglyss met endpoints in Phase 3b ADtouch study
Eli Lilly (LLY) and Company announced that ebglyss monotherapy met its primary and secondary endpoints at Week 16 in the Phase 3b ADtouch study, showing significant and rapid improvements in…
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as ea...
Eli Lilly reports results from TRIUMPH-2 Phase 3 trial
Eli Lilly (LLY) and Company announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon tr...
Lilly's experimental drug cuts weight by 21% in diabetes trial
Eli Lilly said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial.
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesi...
Novo vs. Eli Lilly: Study Shows Ozempic Advantage over Mounjaro — Why This Matters for NVO Investors
Danish drug giant Novo ($NVO), in a Tuesday press statement, announced key findings from a real-world study that pitched its diabetes drug against Eli Lilly’s ($LLY) medication. The study is…
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compa...
Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis
Eli Lilly (LLY) announced results from a new analysis showing that Zepbound – tirzepatide – 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater weight…
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity Participants receiving Zepbound 15 mg had more than three times the odds of achieving at leas...
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
Eli Lilly said its oral obesity drug, Foundayo, offers greater weight loss and better blood sugar control than a higher dose of Novo Nordisk's Ozempic pill in adults with type 2 diabetes, citing dat...
Eli Lilly announces positive results from study of Foundayo 17.2 mg
Eli Lilly (LLY) and Company announced results from a new analysis showing that Foundayo 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral…
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-t...
Eli Lilly CEO tells Bloomberg sees more deals in untapped areas
Eli Lilly (LLY) CEO Dave Ricks said in an interview with Bloomberg that he sees the company doing more deals in untapped areas and sees deals that are “a little…
Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan
JPMorgan raised the firm’s price target on Eli Lilly (LLY) to $1,500 from $1,400 and keeps an Overweight rating on the shares ahead of the Q3 report on October 29.